[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646438":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":60,"collaborators":10,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Secukinumab Cohort",null,"Adult patients with plaque psoriasis (with or without PsA) and MASLD initiating secukinumab in routine clinical practice in Spain.",[13],{"name":14,"affiliation":14,"role":15},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":14,"role":18,"phone":10,"phoneExt":10,"email":10},[23,37,44,52],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Novartis Investigative Site","RECRUITING","Badalona","Barcelona","08916","Spain","ES",{"type":32,"coordinates":33},"Point",[34,35],2.24741,41.45004,{"lat":35,"lon":34},{"facility":24,"status":25,"city":27,"state":10,"zip":38,"country":29,"countryCode":30,"cosmosGeoPoint":39,"geoPoint":43,"contacts":10},"08035",{"type":32,"coordinates":40},[41,42],2.15899,41.38879,{"lat":42,"lon":41},{"facility":24,"status":25,"city":45,"state":10,"zip":46,"country":29,"countryCode":30,"cosmosGeoPoint":47,"geoPoint":51,"contacts":10},"Madrid","28041",{"type":32,"coordinates":48},[49,50],-3.70256,40.4165,{"lat":50,"lon":49},{"facility":24,"status":25,"city":53,"state":10,"zip":54,"country":29,"countryCode":30,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Málaga","29010",{"type":32,"coordinates":56},[57,58],-4.42034,36.72016,{"lat":58,"lon":57},{"type":61,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100646438","a-study-to-estimate-secukinumab-retention-rate-in-psoriasis-patients-with-masld-100646438",false,"NCT07683065","A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD","SEC-HOPE: A Multicenter Retrospective Cohort Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD","SEC-HOPE","Inclusion criteria:\n\n* Patients with a first recorded secukinumab prescription between 01 January 2021 and 31 December 2023.\n* Patients aged ≥18 years at index date.\n* Patients with no prior secukinumab exposure in available EMR history.\n* Secukinumab must be patient's first-, second-, or third-line biologic therapy for psoriasis\u002Fpsoriatic arthritis (PsA).\n* Patients with documented administration per Summary of Product Characteristics dosing recommendations (SmPC).\n* Patients with confirmed plaque psoriasis with or without PsA.\n* Patients with at least one cardiometabolic risk factor.\n* Patients with a confirmed MASLD diagnosis.\n* Patients with baseline laboratory data available.\n\nExclusion criteria:\n\n* Patients with evidence of MASLD absence.\n* Patients with malignant liver disease.\n* Patients with a history of liver transplantation.\n* Patients with alcohol use disorder.\n* Patients with other chronic liver diseases.\n* Patients with diseases or treatments which cause thrombocytopenia.\n* Patients with decompensated cirrhosis.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years","100 Years",{"count":74,"type":75},150,"ESTIMATED","OBSERVATIONAL","This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis \\[PsA\\]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.",[79,80],"Plaque Psoriasis","Metabolic Dysfunction-Associated Steatotic Liver Disease",[82,83],"Plaque psoriasis","MASLD Hepatic Biomarkers Trajectories","2026-08-13",{"date":86,"type":87},"2026-08-14","ACTUAL",{"date":89,"type":87},"2026-07-08",{"date":91,"type":75},"2027-01-15",{"name":14,"class":6},4]